![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » Human Genome partners with FivePrime
Human Genome partners with FivePrime
March 17, 2011
Human Genome Sciences said it will develop and commercialize a drug for multiple cancers from FivePrime Therapeutics in the U.S., Canada and European markets, according to a Reuters report.
FivePrime Therapeutics will get an upfront license payment of $50 million and will be eligible to receive up to $445 million in milestone payments, along with double-digit royalties on net sales.
FivePrime will retain minority co-promotion rights in the U.S. and full development and commercialization rights in the rest of world, including Asia, the companies said in a statement.
The drug, FP-1039, targets multiple fibroblast growth factor ligands. It is currently in mid-stage trials for a form of endometrial cancer.
Upcoming Events
-
21Oct